5 Most Profitable Pharmaceutical Stocks Now

In this piece, we will take a look at five most profitable pharmaceutical stocks now. For more stocks, head on over to 12 Most Profitable Pharmaceutical Stocks Now.

5. AbbVie Inc. (NYSE:ABBV)

Trailing Twelve Month Net Income: $11.8 billion

Number of Hedge Fund Holders in Q3 2022:

AbbVie Inc. (NYSE:ABBV) is an American pharmaceutical company with treatments for several diseases such as psoriasis, different kinds of cancers, and arthritis, among others. The firm is headquartered in North Chicago, Illinois.

AbbVie Inc. (NYSE:ABBV) had some disappointing news for investors in February 2023 when it announced that sales of its arthritis drug in the U.S. will drop by 37% this year due to competition from cheaper alternatives. 80 of the 920 hedge funds polled by Insider Monkey in Q3 2022 had invested in the company.

AbbVie Inc. (NYSE:ABBV)’s largest investor is Cliff Asness’ AQR Capital Management which owns 1.4 million shares that are worth $228 million.

4. Roche Holding AG (SWX:ROG.SW)

Trailing Twelve Month Net Income: $13.44 billion (1CHF = 1.08USD)

Number of Hedge Fund Holders in Q3 2022: N/A

Roche Holding AG (SWX:ROG.SW) is a Swiss healthcare and pharmaceutical company that is headquartered in Basel. The firm makes and sells a wide variety of drugs for cancer, ulcers, heart problems, insomnia, and other diseases. Roche Holding AG (SWX:ROG.SW) won a major reprieve in February 2023 when a French court canceled a $528 million fine against the company for allegedly engaging in anticompetitive practices related to eye treatment.

3. Merck & Co., Inc. (NYSE:MRK)

Trailing Twelve Month Net Income: $14.5 billion

Number of Hedge Fund Holders in Q3 2022: 82

Merck & Co., Inc. (NYSE:MRK) is an American healthcare giant that is a Fortune 500 company and makes and sells products to treat cancer, diabetes, chickenpox, and other diseases.

Merck & Co., Inc. (NYSE:MRK) announced a $1 billion deal in February 2023 through which it will team up with another firm to develop treatments for immune system disorders. Insider Monkey took a look at 920 hedge fund portfolios for last year’s third quarter to determine that 82 had bought the firm’s shares.

Merck & Co., Inc. (NYSE:MRK)’s largest investor is Ken Fisher’s Fisher Asset Management which owns 12 million shares that are worth $1.3 billion.

2. Johnson & Johnson (NYSE:JNJ)

Trailing Twelve Month Net Income: $17.9 billion

Number of Hedge Fund Holders in Q3 2022: 85

Johnson & Johnson (NYSE:JNJ) is a healthcare and pharmaceutical company that makes and sells drugs and other products such as supplements. The firm is based in New Brunswick, New Jersey.

Johnson & Johnson (NYSE:JNJ) scored a big win in February 2023 when Alcon announced that it will pay the firm $199 million to settle legal disputes surrounding laser eye treatments. Insider Monkey’s third quarter of 2022 survey covering 920 hedge funds revealed that 85 had bought the company’s shares.

Johnson & Johnson (NYSE:JNJ)’s largest investor is Ken Fisher’s Fisher Asset Management which owns six million shares that are worth $1 billion.

1. Pfizer Inc. (NYSE:PFE)

Trailing Twelve Month Net Income: $31 billion

Number of Hedge Fund Holders in Q3 2022:

Pfizer Inc. (NYSE:PFE) is an American pharmaceutical giant that is one of the oldest companies of its kind after being set up in 1849. It sells medicines and vaccines for a wide variety of diseases such as heart problems, mental health, and liver disorders.

Pfizer Inc. (NYSE:PFE) announced in February 2023 that it will stop trials of a vaccine due to to a breach of guidelines by a third party. As September 2022 ended, 77 of the 920 hedge funds polled by Insider Monkey had invested in the firm.

Pfizer Inc. (NYSE:PFE)’s largest investor is Cliff Asness’ AQR Capital Management which owns 9.8 million shares that are worth $502 million.

Disclosure: None. You can also take a peek at 25 Most Famous Companies in the World and 10 Hot Healthcare Stocks To Buy Now.

Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Follow Insider Monkey on Twitter